Dr Jason Girkin completed a first-class research honours degree in 2011 in the Bachelor of Biomedical Sciences and Pharmacy, focusing on the role of early life viral infections, and the initial events of the host-response to virus infection, linking maladaptive innate immunity to the development of asthma.
After completing his honours degree, Jason went on to conduct PhD studies in Immunology and Microbiology. His thesis focused on the role of rhinovirus infection and novel molecular signaling pathways in asthma attacks and was the culmination of four original scientific journal article publications.
His PhD candidature was supported by the Australian Post Graduate Award scholarship and the Vice Chancellors Award scholarship.
Jason’s postdoctoral career has focused on innate immunity in the respiratory tract, antiviral responses and novel therapeutics for prophylactic treatment of viral-induced disease.
Jason’s contribution to this field has resulted in the clinical trials for the development of an immune-activating small molecule for the treatment and prevention of COVID-19 and Influenza.
